Risk & Leverage

Apollo Commercial Real Estate Finance offers a tempting 10% yield, but can it last? We dive into the risks and rewards of this high-stakes CRE play.

Reborn Coffee touts a tech-driven global expansion, but a looming Nasdaq delisting and deep financial losses paint a much more complicated picture.

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

Facing an OSC probe and audit delays, the legal tech firm is now seeking court relief, raising red flags for investors about its governance and finances.

Prospect Enhanced Yield Fund's debut 9% distribution tempts income seekers, but a look into the structured credit market reveals a complex risk-reward.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

Lion Group is diversifying its crypto-heavy treasury with Bitcoin. Is this a savvy move in a cool market or a high-stakes bet for a volatile company?